Reishi Mushroom: The Definitive Guide

What is reishi mushroom?

Reishi usually refers to Ganoderma lucidum, also called lingzhi. Product labels may describe fruiting body, cultured mycelium, mycelium, cracked spores, spore powder or a standardized polysaccharide or triterpene extract. Those materials do not share one composition or one clinical result.

Health Canada's October 2025 mushroom monograph accepts dried cultured mycelium, fruiting body and mycelium. It assigns preparation-specific licensing quantities and several traditional or herbal claims, but it is not a clinical trial and does not prove that a retail product prevents infection, treats cancer or controls diabetes. [1]

The most useful clinical conclusion is narrower than the marketing: a few product-specific studies report symptom or immune-marker signals, while direct controlled studies of glucose, lipids and inflammation are negative. Cancer studies concern reishi beside standard treatment, not instead of it.

Typical Reishi Protocols

There is no RDA, AI or UL for reishi. A dried-equivalent amount cannot make a spore powder, fruiting-body extract and purified polysaccharide peptide equivalent.

Titration

The selected evidence does not establish a universal step-up schedule.

Timing

Health Canada's current monograph directs G. lucidum products to be taken with food. Trials do not establish morning, evening or fasted superiority.

Duration

Selected trials lasted eight to 16 weeks. This does not establish indefinite safety or a guaranteed time to benefit.

Stopping

No evidence-based taper exists. Stop and seek review for allergy, unusual bleeding, jaundice, dark urine, severe nausea or a new abnormal laboratory result.

What is reishi commonly used for?

People use reishi for fatigue, stress, sleep, immune support, glucose or cholesterol control, liver health and cancer support. Traditional-use claims and laboratory mechanisms are not proof of these outcomes.

Human evidence is scattered across different products and populations. An older proprietary-extract study reported fatigue and well-being changes under a neurasthenia diagnosis. Better direct cardiometabolic trials were null. Cancer reviews describe possible adjunctive signals from weak studies, without reliable long-term survival evidence. [2], [3], [4], [6]

Which form and label details matter?

Read a reishi label in this order:

1. Species: Ganoderma lucidum, rather than only “medicinal mushroom.”
2. Fungal material: fruiting body, cultured mycelium, mycelium or spores.
3. Process: whole powder, aqueous extract, ethanol extract or purified fraction.
4. Dried equivalent: actual extract per serving and starting-material equivalent.
5. Markers: beta-glucans or polysaccharides, triterpenes or ganoderic acids, with the assay method.
6. Other ingredients: blends cannot reveal reishi's contribution.

“Dual extract,” “cracked spores” and a high polysaccharide percentage do not prove clinical superiority. Starch can inflate nonspecific polysaccharide results, so beta-glucan and alpha-glucan methods matter. A label marker still does not make a product equivalent to Ganopoly or GLPP.

What does the human evidence show?

Glucose, lipids and inflammation

The 2016 trial randomized 84 people with type 2 diabetes and metabolic syndrome to 3 g/day of G. lucidum, the same amount combined with Cordyceps sinensis, or placebo for 16 weeks. The two intervention groups were combined for analysis. Neither HbA1c nor fasting glucose improved; the many secondary outcomes were also null, with no overall increase in adverse events. [2]

The 2015 Cochrane review found five eligible cardiovascular-risk trials and could analyze three placebo comparisons using 1.4 to 3 g/day for 12 to 16 weeks. It found no support for treating cardiovascular risk factors in people with type 2 diabetes. The 2016 trial supplies a direct modern null result rather than a reason to recommend reishi for glucose or cholesterol. [2], [7]

In 2026, Abshori and colleagues randomized 60 adults with obesity and cardiometabolic syndrome to GLPP 250 mg three times daily or placebo for eight weeks. IL-6, TNF-alpha, hsCRP, nitric oxide, total cholesterol, triglycerides, HDL, LDL and BMI did not differ between groups. Concomitant medicines, unmeasured lifestyle factors, short duration and sample size limit the study, but they do not reverse its null findings. [3]

Cancer and immune claims

A Cochrane review included five randomized trials with 373 participants, largely from China. Some pooled tumor-response, quality-of-life and immune-marker results favored reishi when added to chemotherapy or radiotherapy. No trial reported long-term survival, study methods and reporting were poor, and reishi alone did not show the same tumor-regression signal. [4]

This evidence does not establish cancer prevention, longer survival, a safe interaction with every treatment or a replacement for oncology care. Immune-marker changes such as CD3, CD4 or CD8 percentages do not prove fewer infections or better cancer outcomes. Any adjunctive use belongs with the oncology team.

Fatigue, stress and sleep

Tang and colleagues randomized 132 people meeting an ICD-10 neurasthenia diagnosis to Ganopoly 1,800 mg three times daily or placebo for eight weeks; 123 were assessable. Clinical Global Impression, fatigue and well-being scales favored the extract. The study was conducted more than 20 years ago, used a proprietary preparation and a diagnosis that does not map cleanly to modern causes of fatigue. It does not prove treatment for insomnia, depression, long COVID or unexplained fatigue. [6]

How might it work?

Reishi products can contain beta-glucans and other polysaccharides, triterpenes including ganoderic acids, sterols and proteins. Laboratory studies examine pattern-recognition receptors, cytokines, platelet function, glucose pathways, oxidative stress and tumor-cell signaling.

Those mechanisms help define research questions. They do not show that a retail oral product reaches a clinically useful exposure or improves a health outcome. An immune biomarker can move without preventing infection, and tumor-cell death in a dish is not cancer treatment.

What are the risks and interactions?

Reported effects include nausea, sleep disturbance and allergy. MSK lists liver injury and advises review with warfarin or other blood thinners and with immunosuppressants. Clinical interaction incidence is unknown, so the safe conclusion is disclosure and medicine review rather than a precise universal washout. [5]

Rare case reports describe liver injury, including a 2023 report with alcohol use as an important co-exposure. Case reports cannot estimate incidence or prove that every product carries the same risk, but they justify attention to jaundice, dark urine, pale stools, persistent upper-abdominal pain, severe nausea or marked fatigue. [8]

MSK also warns that reishi spore powder can raise CA72-4 and interfere with interpretation in cancer care. Tell the ordering clinician and laboratory the product and stop date rather than assuming an abnormal result represents disease progression. [5]

Health Canada's current monograph assigns G. lucidum an allergy stop statement. It does not attach its general pregnancy warning to reishi, but absence of that monograph statement is not evidence of pregnancy or breastfeeding safety. Evidence is inadequate, so review use with the prenatal or lactation team. [1]

Seek prompt care for severe allergy, uncontrolled bleeding, black stools, vomiting blood, jaundice, confusion or severe persistent abdominal symptoms. Do not change chemotherapy, immunotherapy, immunosuppression, diabetes medicine or anticoagulation because reishi was started or stopped.

Legal status in the United States and Canada

In the United States, reishi is sold as a dietary supplement. FDA does not approve supplements for safety and effectiveness before sale; a product cannot legally claim to treat cancer, diabetes, liver disease or infection. [9]

In Canada, licensed natural health products carry an NPN. The October 2025 mushroom monograph defines eligible G. lucidum parts, preparation-specific quantities, claims, with-food direction and allergy statement. [1]

What should you monitor?

Record species, fungal material, extraction solvent, dried equivalent, marker assay, other ingredients, lot, amount and start date. Choose one outcome before starting. Fatigue and sleep logs can organize a conversation but cannot diagnose anemia, thyroid disease, depression, sleep apnea, infection or cancer.

Glucose, lipids, liver tests, blood counts, coagulation, tumor markers and cancer response belong to the treating team. A consumer trend cannot replace these measurements or show that reishi caused a change.

What happens when you stop?

The selected evidence does not establish withdrawal or a taper. A symptom returning after stopping still does not prove causation. Coordinate changes with the treating team when reishi is used during cancer care, immunosuppression, anticoagulation or evaluation of liver injury.

How should it be stored?

Follow the product label. Keep powders, capsules and extracts closed, dry, away from heat and children, and discard damaged, damp, unusually scented or expired products. Liquid extracts may have different instructions.

How does reishi compare with other approaches?

Diabetes, blood pressure and lipid management have established lifestyle and medical approaches with measured targets. A 16-week null trial provides no basis for replacing them with reishi. Persistent fatigue or poor sleep requires assessment of cause before adding several supplements.

Cordyceps, lion's mane, chaga and turkey tail have different species, parts, extracts and evidence. Turkey-tail PSK or PSP oncology studies do not transfer to reishi. A mushroom blend makes benefit and harm harder to attribute.

What do public communities add?

Public discussions identify practical questions about bitter taste, sleep timing, fruiting body versus mycelium, spores and extraction. They cannot authenticate species, measure beta-glucans, diagnose liver injury, predict medicine interactions or estimate cancer benefit. Anecdotes do not set the dose or certainty in this guide.

Common questions

Does reishi boost the immune system?

Some studies measured immune markers, but a marker change does not prove fewer infections or better cancer outcomes. Immunosuppressed people should review use with their treating team. [4], [5]

Does reishi lower blood sugar or cholesterol?

Direct evidence is negative. A 16-week trial found no benefit for HbA1c, fasting glucose or secondary cardiometabolic outcomes, and a 2026 GLPP trial found null lipid and inflammatory results. [2], [3]

Can reishi treat cancer?

No. Older weak trials studied it beside chemotherapy or radiotherapy, did not report long-term survival and do not support first-line or stand-alone treatment. [4]

Does reishi help fatigue or sleep?

One older proprietary-extract trial reported symptom improvements under a neurasthenia diagnosis. It does not establish a general insomnia or fatigue treatment. [6]

Is fruiting body better than mycelium or spores?

No universal clinical ranking is established. Identity and testing matter, but clinical evidence remains tied to the exact preparation studied.

Can reishi be taken with warfarin?

MSK advises healthcare review because reishi may raise bleeding risk. Do not assume safety in the absence of robust interaction trials. [5]

Can reishi affect laboratory results?

Yes. MSK reports that reishi spore powder may elevate CA72-4, which can complicate interpretation in cancer care. Disclose product and timing. [5]

Is reishi safe during pregnancy or breastfeeding?

Reliable safety evidence is inadequate. Discuss use with the prenatal or lactation team rather than interpreting missing data as safety.

Glossary

Terms used in this guide.

Fruiting body

The spore-producing fungal structure, distinct from cultured mycelium and spores.

Mycelium

A network of fungal filaments grown in culture or on a substrate.

GLPP

A Ganoderma lucidum polysaccharide peptide preparation studied at 250 mg three times daily in a 2026 trial.

Surrogate endpoint

A marker used instead of an outcome people directly experience, such as an immune-cell percentage rather than infection or survival.

Adjunctive treatment

Something added to standard care rather than used as its replacement.

CA72-4

A laboratory tumor marker that can be elevated by reishi spore powder and therefore requires contextual interpretation.

Titration

Changing an amount in planned steps. The selected evidence does not establish a universal reishi titration.

How this guide was researched

This draft used Health Canada's October 2025 mushroom monograph, the 2015 cardiovascular Cochrane review, direct randomized trials from 2005, 2016 and 2026, the 2016 cancer Cochrane review, MSK's clinical record, a liver-injury case report and FDA guidance. Searches covered identity, preparation, polysaccharides, cardiometabolic outcomes, fatigue, immune markers, cancer, bleeding, immunosuppression, liver injury and laboratory interference.

Corrections to the legacy manuscript include replacing a generic dose range with source-specific schedules; adding the 2026 null trial; retaining direct metabolic nulls; separating immune markers from infection and cancer outcomes; avoiding the phrase “gold standard”; and removing universal best-form, sleep, cycling, detox, liver-protection and bioavailability claims. Evidence was refreshed October 9, 2026.

How this guide was made

The source ledger stores preparation, population, amount, duration, outcomes and limitations. Primary studies support protocol rows; systematic reviews define evidence certainty; official sources frame Canadian licensing and U.S. regulation. Draft status means scientific, French-parity, asset and rendered-page review remain separate gates.

Sources

Related guides